<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345342</url>
  </required_header>
  <id_info>
    <org_study_id>CR108390</org_study_id>
    <secondary_id>R092670PSY3015</secondary_id>
    <secondary_id>2017-001941-28</secondary_id>
    <nct_id>NCT03345342</nct_id>
  </id_info>
  <brief_title>A Study of Paliperidone Palmitate 6-Month Formulation</brief_title>
  <official_title>A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that injection cycles consisting of a single
      administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2
      sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg
      eq.) for the prevention of relapse in participants with schizophrenia previously stabilized
      on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M
      (350 or 525 mg eq.).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis of this study is that the efficacy of PP6M is non-inferior to PP3M for
      preventing relapse in participants with schizophrenia who were previously stabilized on
      corresponding doses of PP1M or PP3M. The study consists of mainly 3 phases: a screening phase
      (up to 28 days), a maintenance phase (of 1 or 3 months), and a double-blind phase (of 12
      months [neither the researchers nor the participants know what treatment the participant is
      receiving]). Additional/conditional phases include a transition phase (before maintenance
      phase). Study evaluations include efficacy, pharmacokinetics, pharmacodynamics, and safety.
      The study duration will vary from approximately 13 months to 19 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Actual">May 8, 2020</completion_date>
  <primary_completion_date type="Actual">May 8, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse During the Double-Blind (DB) Phase</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Time to relapse:Time between participant randomization in DB Phase and first documentation of a relapse event by the end of Month 12 of the DB phase. Relapse:Psychiatric hospitalization;participant had an increase of 25 % in total PANSS score from randomization for 2 consecutive assessments (CA) separated by 3-7 days if score at randomization was &gt;40;had 10 point increase in total PANSS score from randomization for 2 CA separated by 3-7 days if score at randomization was &lt;=40;deliberate self-injury or exhibited violent behavior results in suicide, clinically significant injury;suicidal/homicidal ideation and aggressive behavior;for PANSS items had score of greater than or equal to (&gt;=) 5 after randomization for 2 CA separated by 3-7 days on any of above items if maximum score for these above PANSS items was &lt;=3 at randomization;had score of &gt;=6 after randomization for 2 CA separated by 3-7 days on any of above items if maximum score for these above PANSS items was 4 at randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Total and Subscale Score at Month 3, 6, 9, 12</measure>
    <time_frame>Baseline, Month 3, 6, 9, 12</time_frame>
    <description>The neuropsychiatric symptoms of schizophrenia will be assessed by using the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score at Month 3, 6, 9, 12</measure>
    <time_frame>Baseline, Month 3, 6, 9, 12</time_frame>
    <description>The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to &quot;Normal, not at all ill&quot; and a rating of 7 is equivalent to &quot;Among the most extremely ill participants&quot;. Higher scores indicate worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Personal and Social Performance (PSP) Total Score at Month 3, 6, 9, 12</measure>
    <time_frame>Baseline, Month 3, 6, 9, 12</time_frame>
    <description>The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The results of the assessment are converted to a numerical score from 1 to 100 points, which can be interpreted in 10-point intervals as excellent functioning (91 to 100 points), good functioning (81 to 90 points), mild difficulties (71 to 80 points), etc, as shown in the Manual of Assessments. Scores from 31 to 70 points indicate varying degrees of difficulty, and scores below 30 points indicate functioning so poor that intensive support or supervision is needed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Met the Criteria for Symptomatic Remission</measure>
    <time_frame>Up to 19 months</time_frame>
    <description>Symptomatic remission is defined as having a simultaneous score of mild or less (less than or equal to [&lt;=3] points) on the following 8 items from the PANSS: the positive-symptom items P1 (delusions), P2 (conceptual disorganization), P3 (hallucinatory behavior); the negative-symptom items N1 (blunted affect), N4 (social withdrawal), and N6 (lack of spontaneity); and the general psychopathology items G5 (mannerisms/posturing) and G9 (unusual thought content).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 90 days (Maintenance Phase); up to 365 days (Double-blind Phase)</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin)</measure>
    <time_frame>Up to 90 days (Maintenance Phase); up to 365 days (Double-blind Phase)</time_frame>
    <description>The Cmin is the minimum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM-9) Score</measure>
    <time_frame>Up to 19 months</time_frame>
    <description>TSQM-9 is a 9-item generic participant-reported outcome instrument to assess participant's satisfaction with medication and covers domains of effectiveness, convenience and global satisfaction. The instrument is scored by domain with scores ranging from 0-100 where a lower score indicates lower satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with Participation in Social Roles (SPSR)</measure>
    <time_frame>Up to 19 months</time_frame>
    <description>The SPSR Short Form 8a is a participant-reported outcome used to assess the satisfaction with participation in social roles. The participants are asked to rate 8 items on 5-point Likert scales with scores ranging from 8 to 40, where higher scores represents higher satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Vital Signs, Physical Examinations, Electrocardiogram (ECG), Laboratory Findings, and Injection Site Reactions as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to approximately 19 months</time_frame>
    <description>Number of participants with abnormalities in vital signs, physical examinations, ECG, laboratory findings and injection site reactions will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal Ideation or Behavior Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Up to 19 months</time_frame>
    <description>C-SSRS is a clinician rated assessment of suicidal behavior and / or intent. Scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>Up to 19 months</time_frame>
    <description>The AIMS rates 9 items about dyskinesia on scale as 0 = none, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe. It rates 1 item about the participants's awareness of abnormal movements as 0 = no awareness; 1 = aware, no distress; 2 = aware, mild distress; 3 = aware, moderate distress; and 4 = aware, severe distress. It has 2 yes/no questions about dental status. A total score (ranging from 0 to 28) will be calculated as the sum of items 1 to 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barnes Akathisia Rating Scale (BARS)</measure>
    <time_frame>Up to 19 months</time_frame>
    <description>The BARS assesses akathisia via 1 objective rating and 2 subjective ratings (awareness of restlessness and reported distress related to restlessness); each is scored from 0 to 3 points. It also assesses akathisia via 1 global clinical rating scored from 0 to 5 points. For all items, anchors are provided for each value and higher scores indicate worse akathisia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simpson Angus Scale (SAS)</measure>
    <time_frame>Up to 19 months</time_frame>
    <description>The SAS is led by signs (rather than by symptoms) to measure drug-induced parkinsonism. The modified SAS in this study contains 10 items: 6 items for rigidity (arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, and head rotation); 1 compound item for gait (incorporating gait, posture, and loss of arm swing), and 3 items for tremor, glabellar tap, and salivation. The score ranges between 0 and 4, where the higher score denotes more severe condition of extra pyramidal symptoms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">841</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>PP1M: Transition Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PP1M/PP3M: Maintenance Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PP6M or Placebo: Double-Blind Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PP3M: Double-Blind Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP6M</intervention_name>
    <description>Participants will receive intramuscular injection of PP6M.</description>
    <arm_group_label>PP6M or Placebo: Double-Blind Phase</arm_group_label>
    <other_name>R092670</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP3M 350 mg eq.</intervention_name>
    <description>Participants will receive intramuscular injection of PP3M 350 mg eq.</description>
    <arm_group_label>PP1M/PP3M: Maintenance Phase</arm_group_label>
    <arm_group_label>PP3M: Double-Blind Phase</arm_group_label>
    <other_name>R092670</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP3M 525 mg eq.</intervention_name>
    <description>Participants will receive intramuscular injection of PP3M 525 mg eq.</description>
    <arm_group_label>PP1M/PP3M: Maintenance Phase</arm_group_label>
    <arm_group_label>PP3M: Double-Blind Phase</arm_group_label>
    <other_name>R092670</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP1M</intervention_name>
    <description>Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.</description>
    <arm_group_label>PP1M/PP3M: Maintenance Phase</arm_group_label>
    <arm_group_label>PP1M: Transition Phase</arm_group_label>
    <other_name>R092670</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo.</description>
    <arm_group_label>PP6M or Placebo: Double-Blind Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must meet the diagnostic criteria for schizophrenia according to Diagnostic and
             Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) for at least 6 months
             before screening

          -  Must be receiving treatment with paliperidone palmitate (as either the paliperidone
             palmitate 1-month (PP1M) or paliperidone palmitate 3-month (PP3M) formulation), or
             injectable risperidone, or any oral antipsychotic

          -  Must be able, in the opinion of the investigator, to discontinue any antipsychotic
             medication other than PP1M) or PP3M during the Screening Phase

          -  Must have a full Positive and Negative Syndrome Scale (PANSS) score of less than (&lt;)
             70 points at screening

          -  Must have a body mass index (BMI) between 17 and 40 kilogram (kg)/meter (m)^2
             (inclusive) and must have a body weight of at least 47 kg at screening

          -  Must be willing to receive gluteal injections of medication during the Double-blind
             Phase

        Exclusion Criteria

          -  Must not be receiving any form of involuntary treatment, such as involuntary
             psychiatric hospitalization, parole-mandated treatment, or court-mandated treatment

          -  Must not have attempted suicide within 12 months before screening and must not be at
             imminent risk of suicide or violent behavior, as clinically assessed by the
             investigator at the time of screening

          -  Must not have a DSM-5 diagnosis of moderate or severe substance use disorder (except
             for nicotine and caffeine) within 6 months of screening; however, acute or
             intermittent substance use prior to screening is not exclusionary, depending upon the
             clinical judgment of the investigator

          -  Must not have a history of neuroleptic malignant syndrome or tardive dyskinesia

          -  Must not have a history of intolerability or severe reactions to moderate or higher
             doses of antipsychotic medications and must not have any other factors that would, in
             the judgment of the investigator, indicate that treatment with moderate or higher
             doses of paliperidone palmitate would be intolerable or unsafe
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodland Research Northwest</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pharmaceutical Research Institute, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative NeuroScience Network</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy East</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SF-Care, Inc</name>
      <address>
        <city>San Rafael</city>
        <state>California</state>
        <zip>94901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Life Medical Research Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintex Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Center Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uptown Research Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Behavioral Health Hospital</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Hospitals Wichita, Inc</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherry Street Services, Inc.</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America Inc</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wexner Medical Center at the Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Search Trials of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric and Behavioral Solutions</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84105-2425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación para el Estudio y Tratamiento de las Enfermedades Mentales</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1133AAH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEN</name>
      <address>
        <city>Cordoba</city>
        <zip>X5004FJF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Prof. Leon S. Morra</name>
      <address>
        <city>Cordoba</city>
        <zip>X5009BIN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurociencias San Agustín</name>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Privada de Salud Mental Santa Teresa de Ávila</name>
      <address>
        <city>La Plata</city>
        <zip>B1904ADM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.I.A.P. (Centro de investigación y Asistencia en Psiquiatría)</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Trials Victoria</name>
      <address>
        <city>Noble Park</city>
        <zip>3174</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial Tech Tecnologia em Pesquisas com Medicamentos</name>
      <address>
        <city>Curitiba</city>
        <zip>80240-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Bairral de Psiquiatria</name>
      <address>
        <city>Itapira</city>
        <zip>13970-905</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Psiquiatria e Pesquisas Sandra Ruschel</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22270-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Proesq - Unifesp</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPQuali Pesquisa Clinica LTDA ME</name>
      <address>
        <city>São Paulo</city>
        <zip>01228-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Psiquiatria - Hcfmusp</name>
      <address>
        <city>São Paulo</city>
        <zip>05403010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Center Prof. Dr. Ivan Temkov</name>
      <address>
        <city>Bourgas</city>
        <zip>8001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Psychiatric Hospital Pazardzhik</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Sveti Georgi'-Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Psychiatric HospitalDr.Georgi Kissiov</name>
      <address>
        <city>Radnevo</city>
        <zip>6260</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Mental Health Prof.N.Shipkovenski EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1377</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Intermedica, OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulance, MUDr. Marta Holanova</name>
      <address>
        <city>Brno</city>
        <zip>61500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuropsychiatrieHK, s.r.o.</name>
      <address>
        <city>Hradec Kralove-Vekose</city>
        <zip>50341</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A-Shine s.r.o.</name>
      <address>
        <city>Plzen</city>
        <zip>31200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Neuropsychiatricke pece</name>
      <address>
        <city>Prague</city>
        <zip>18600</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulance MUDr. Simona Papezova</name>
      <address>
        <city>Prague</city>
        <zip>19000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRAGTIS s.r.o.</name>
      <address>
        <city>Praha 2</city>
        <zip>12000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.S. Charles Perrens</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU La Colombière</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caremeau</name>
      <address>
        <city>Nimes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Anne</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte Musse</name>
      <address>
        <city>Toulon Cedex</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwai Chung Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Józsefvarosi Szent Kozma Egészségügyi Központ</name>
      <address>
        <city>Budapest</city>
        <zip>1084</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz</name>
      <address>
        <city>Győr</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Mathe es Tarsa Bt.</name>
      <address>
        <city>Kalocsa</city>
        <zip>6300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Kft.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ratandeep Multispeciality Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Ramachandra Medical Centre</name>
      <address>
        <city>Chennai</city>
        <zip>600116</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asha hospital</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ahana Hospitals</name>
      <address>
        <city>Madurai</city>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinaya Hospital and Research Center</name>
      <address>
        <city>Mangalore</city>
        <zip>575003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College Hospital</name>
      <address>
        <city>Manipal</city>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical Development Center Pvt Ltd</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deva Institute of Health Care and Research Pvt Ltd</name>
      <address>
        <city>Varanasi</city>
        <zip>221005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Psichiatrica - Università di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <zip>09127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Salute Mentale</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Universita degli Studi di Napoli - Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Roma 'La Sapienza' - Azienda Ospedaliera Sant Andrea</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National Univ Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical center, CHA University</name>
      <address>
        <city>Seongnam</city>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bahagia Ulu Kinta</name>
      <address>
        <city>Ipoh</city>
        <zip>31250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabipros SC.</name>
      <address>
        <city>Mexico City</city>
        <zip>07810</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Neuropsique</name>
      <address>
        <city>Monterrey</city>
        <zip>64610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Clinicos y Especialidades Medicas, S.C.</name>
      <address>
        <city>Monterrey</city>
        <zip>64620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infosame/Research</name>
      <address>
        <city>Monterrey</city>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Atención e Investigación Cardiovascular del Potosí, S.C.</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk</name>
      <address>
        <city>Bialystok</city>
        <zip>15-404</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski</name>
      <address>
        <city>Bialystok</city>
        <zip>15-464</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Opieki Zdrowotnej w Chelmnie</name>
      <address>
        <city>Chelmno</city>
        <zip>86-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych PI-House sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. H. Klimontowicza, Oddzial Psychiatryczny</name>
      <address>
        <city>Gorlice</city>
        <zip>38-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS</name>
      <address>
        <city>Leszno</city>
        <zip>64-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Luxmed Sp z o o</name>
      <address>
        <city>Lublin</city>
        <zip>20-109</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poradnia Zdrowia Psychicznego 'Syntonia' w Pruszczu Gdanskim</name>
      <address>
        <city>Pruszcz Gdanski</city>
        <zip>83-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Specjalistyczne Centrum Zdrowia im. Prof. Jana Mazurkiewicza w Pruszkowie</name>
      <address>
        <city>Pruszkow</city>
        <zip>05-802</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Psychiatric Hospital</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Psychiatric Hospital #3 Named After V.A. Gilyarovsky</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Clinical hospital 1 named after N.A. Alekseev</name>
      <address>
        <city>Moscow</city>
        <zip>117152</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizny Novgorod clinical psychiatric hospital 1</name>
      <address>
        <city>Nizny Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov Regional Psychiatric hospital named after St. Sofia</name>
      <address>
        <city>Saratov</city>
        <zip>410060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychoneurological Dispensary of Frunzensky District</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychoneurological dispensary 10</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Petersburg Bekhterev Psychoneurological Research Institute</name>
      <address>
        <city>St-Petersburg</city>
        <zip>192109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychoneurological dispensary 1</name>
      <address>
        <city>St-Petersburg</city>
        <zip>199178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychoneurological Dispensary #4</name>
      <address>
        <city>St.Peterburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Mental Health</name>
      <address>
        <city>Tomsk</city>
        <zip>634014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flexivest 14 Research</name>
      <address>
        <city>Cape Town</city>
        <zip>7550</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gert Bosch - Pretoria South Africa</name>
      <address>
        <city>Pretoria</city>
        <zip>0042</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juan Schrönen - Western Cape South Africa</name>
      <address>
        <city>Welgemoed</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Internac. Neurociencias Aplicadas</name>
      <address>
        <city>Barcelona</city>
        <zip>8006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Salud Mental La Corredoria</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. El Bierzo</name>
      <address>
        <city>Ponferrada</city>
        <zip>24404</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Prov. de Zamora</name>
      <address>
        <city>Zamora</city>
        <zip>49021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Numune Research and Training Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abdurrah Yurtarslan Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>6200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erenkoy Mental Health Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34736</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Selcuk University, Medical School, Department of Psychiatry</name>
      <address>
        <city>Konya</city>
        <zip>42130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakarya University Medical Faculty Psychiatry Department</name>
      <address>
        <city>Sakarya</city>
        <zip>54187</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association</name>
      <address>
        <city>Glevakha</city>
        <zip>8630</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Institute of Neurology, Psychiatry and Narcology of NAMSU</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council</name>
      <address>
        <city>Kherson</city>
        <zip>73488</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Territorial Medical Incorporation 'Psychiatry'</name>
      <address>
        <city>Kyiv</city>
        <zip>04080</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution 'Lviv Regional Clinical Psycho-Neurological Dispensary'</name>
      <address>
        <city>Lviv</city>
        <zip>79017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNCE of the Lviv Regional Council 'Lviv Regional Clinical Psychiatric Hospital'</name>
      <address>
        <city>Lviv</city>
        <zip>79021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNCE Odesa regional psychiatric hospital #2 Odesa regional council</name>
      <address>
        <city>Oleksandrivka</city>
        <zip>67513</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council'</name>
      <address>
        <city>Smila</city>
        <zip>20708</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNCE 'Vinnytsya RC Psychoneurological Hospital n.a. O.I. Yushchenko Vinnytsya RC'</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Romania</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

